VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IMMP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IMMPImmutep Limited
$0.45$66M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

IMMP logoImmutep Limited(IMMP)Earnings, Financials & Key Ratios

IMMP•NASDAQ
$0.45
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryOncology Therapeutics Developers
AboutImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.Show more
  • Revenue$5M+31.3%
  • EBITDA-$124M-44.4%
  • Net Income-$61M-43.8%
  • EPS (Diluted)-0.42-16.7%
  • Gross Margin-1117.55%-13.9%
  • EBITDA Margin-2464.17%-10.0%
  • Operating Margin-2506.49%-9.3%
  • Net Margin-1218.02%-9.5%
  • ROE-36.88%-40.7%

IMMP Price & Volume

Immutep Limited (IMMP) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Outpace Milestone Revenue Growth

Investment Thesis • Updated 2026Q2

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency

Key Thesis Takeaways

  • Immutep remains a high-risk, pre-revenue biotechnology firm heavily reliant on milestone-driven funding to sustain its intensive LAG-3 oncology research pipeline.
  • While the company maintains a clean balance sheet with a debt-to-equity ratio of 0.01, the persistent widening of operating losses and rapid depletion of cash reserves suggest significant long-term financing risks.
  • Investors should monitor the company's ability to reach critical clinical data readouts before the current $72.7M cash position is exhausted by ongoing R&D requirements.

Verdict Logic

the company's reliance on non-commercial milestone revenue and the rapid depletion of cash reserves from $161.8M in 2024Q4 to $72.7M in 2026Q2 present substantial risks to long-term equity value.

IMMP Growth Metrics

Immutep Limited (IMMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years9.19%
5 Years-7.59%
3 Years209.35%
TTM121.22%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-65.81%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-12.5%

Return on Capital

10 Years-61.88%
5 Years-57.55%
3 Years-65.19%
Last Year-75.4%

IMMP Recent Earnings

Immutep Limited (IMMP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (70%)●Beat Revenue 4/12 qtrs (40%)
Q1 2026Latest
Feb 24, 2026
Metric
Actual
Est
EPS
$0.15-9.0%
$0.14
Rev
$4M-42.0%
$7M
Q3 2025
Aug 28, 2025
Metric
Actual
Est
EPS
$0.18-44.0%
$0.12
Rev
$1M
—
Q1 2025
Feb 26, 2025
Metric
Actual
Est
EPS
$0.01+88.7%
$0.08
Rev
$2M+349.7%
$433,237
Q3 2024
Aug 30, 2024
Metric
Actual
Est
EPS
$0.01+86.1%
$0.08
Rev
$1M-6.6%
$1M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 24, 2026
$0.15vs $0.14-9.0%
$4Mvs $7M-42.0%
Q3 2025Aug 28, 2025
$0.18vs $0.12-44.0%
$1M
Q1 2025Feb 26, 2025
$0.01vs $0.08+88.7%
$2Mvs $433,237+349.7%
Q3 2024Aug 30, 2024
$0.01vs $0.08+86.1%
$1Mvs $1M-6.6%
Based on last 12 quarters of dataView full earnings history →

Latest IMMP News

Recent stock market news and headlines for Immutep Limited (IMMP)

PRNewsWire·Jun 29, 2026
Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP

LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Peers Comparison

Key metrics vs top competitors for Immutep Limited (IMMP)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
IMMP logoIMMPImmutep LimitedCurrent
$0.45$65.98M-1.5431.28%-1218.02%-36.88%—
NKTX logoNKTXNkarta, Inc.
$3.38$241.82M-2.40——-30.9%—
AGEN logoAGENAgenus Inc.
$3.50$145.75M-1029.4110.37%52.16%——
IMVT logoIMVTImmunovant, Inc.
$40.09$8.23B-14.47——-68.16%—
RCUS logoRCUSArcus Biosciences, Inc.
$30.25$3.05B-9.19-4.26%-156.36%-68.97%—
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$4.75$192.85M3.8936.55%-19.55%-3.39%—

Compare IMMP vs Peers

Immutep Limited (IMMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NKTX

Most directly comparable listed peer for IMMP.

Scale Benchmark

vs MRK

Larger-name benchmark to compare IMMP against a more recognizable public peer.

Peer Set

Compare Top 5

vs NKTX, AGEN, IMVT, RCUS

Get notified when IMMP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

IMMP Frequently Asked Questions

Immutep Limited (IMMP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Immutep Limited's revenue?

Immutep Limited (IMMP) reported $12.8M in revenue for fiscal year 2025.

How fast is Immutep Limited growing?

Immutep Limited (IMMP) grew revenue by 31.3% over the past year. This is strong growth.

Is IMMP profitable?

Immutep Limited (IMMP) reported a net loss of $127.8M for fiscal year 2025.

Dividend & Returns
What is IMMP's return on equity?

Immutep Limited (IMMP) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.

What is Immutep Limited's free cash flow?

Immutep Limited (IMMP) had negative free cash flow of $108.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in IMMP back in 2008?

Total return calculator · dividends reinvested · 18+ years of data

See returns →